Clinical Trials Logo

Substance-Related Disorders clinical trials

View clinical trials related to Substance-Related Disorders.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05001789 Suspended - Opioid Use Clinical Trials

Cognitive Functioning in Opioid Use Disorder

Start date: September 21, 2021
Phase: N/A
Study type: Interventional

This outpatient study is designed to examine the potential relationship between non-fatal opioid overdose and cognitive functioning. This study will also examine the impact of computerized working memory training on relevant outcomes (cognition, psychosocial functioning, quality of life, drug use). The training component of the study lasts 1 month, with follow up visits and 1-month and 3-months post training.

NCT ID: NCT04934553 Suspended - Depression Clinical Trials

Amplification of Positivity for Alcohol Use Disorder Co-Occurring With Anxiety or Depression

Start date: May 20, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the feasibility of a protocol in which individuals with comorbid depression or anxiety disorders and alcohol use disorder will be randomized to complete Amplification of Positivity for Alcohol Use Disorder (AMP-A)- a psychological treatment focused on increasing positive thoughts, emotions, and behaviors- or a traditional cognitive-behavioral therapy (CBT) intervention. Assessed outcomes will include participant acceptability and completion rates, participant compliance with the intervention, positive and negative affect, substance use- and depression and anxiety-related symptom severity, and functional disability.

NCT ID: NCT04603781 Suspended - Substance Abuse Clinical Trials

CBD Oil for Reducing Emotional Impact of COVID-19

CBDOIL
Start date: December 4, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Our purpose is to conduct a 4-arm placebo-controlled clinical trial to investigate the relative clinical efficacy of 300 mg. of pure hemp-derived CBD isolate, 300 mg. of full spectrum CBD oil, 300 mg. of broad- spectrum CBD Oil, or Placebo oil among adults presenting with COVID-19 -induced stress reactions including one or more of the following: anxiety, depression, anger, substance use, or sleep disturbance.

NCT ID: NCT04404348 Suspended - Clinical trials for Substance-Related Disorders

Cognitive Rehabilitation for Opioid Abuse-related Cognitive Impairment

Start date: March 6, 2020
Phase: N/A
Study type: Interventional

Research has consistently found that cognitive impairment is common in persons with a history of substance abuse. The most commonly identified impairments across all substances are in attentional and working memory functioning and executive functioning; opioid-specific research finds that memory is an additional area of common impairment. Initial research in applying cognitive rehabilitation methods to substance abuse have shown it to be helpful overall. To develop a cognitive rehabilitation intervention that is effective for opioid abuse, this study will adapt a cognitive training program that has been shown to be effective in other patient groups. Patients in a residential opioid-abuse treatment program will undergo a cognitive evaluation and then be assigned to receive the 4-week cognitive intervention or the 4-week placebo control arm. It is expected that the intervention group will show greater gains on the cognitive post test and will have higher rated treatment adherence and opioid treatment program completion rates.

NCT ID: NCT04352166 Suspended - Opioid-use Disorder Clinical Trials

Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder

Start date: December 15, 2020
Phase: Phase 2
Study type: Interventional

The study is 12-week, randomized, open-label study comparing injectable extended-release buprenorphine (Sublocade) to standard therapy (sublingual buprenorphine), to see if Sublocade will be more helpful in treating opiate use for individuals testing positive for fentanyl and related high potency drugs (HPSO). Those receiving Sublocade will have it administered monthly and dosing will be according to the FDA prescribing instructions of 300mg for the first and second dose and 100mg for the third. Individuals receiving sublingual buprenorphine will receive standard dosing for the entire treatment trial. Participants will be asked to attend the clinic for the first 4 days during week 1 and twice weekly for the remainder of the trial.

NCT ID: NCT03907709 Suspended - Clinical trials for Substance Use Disorders

Effects of In-Home Addiction Treatment for First Responders

Start date: April 8, 2019
Phase:
Study type: Observational

Retrospective analysis to evaluate impact of an in-home addiction treatment program on first responders with substance use disorder.